In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis

Recurrent vulvovaginal candidiasis

(2016) Jack D. Sobel   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth

(2016) Ditte Mølgaard-Nielsen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, againstCandidaandAspergillusspp., including echinocandin- and azole-resistant isolates

(2016) Michael A. Pfaller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors

(2015) Bruna Gonçalves et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

(2014) David S. Perlin   DRUGS

Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States

(2013) Betsy Foxman et al.   Journal of Lower Genital Tract Disease

Effect of pH onIn VitroSusceptibility of Candida glabrata and Candida albicans to 11 Antifungal Agents and Implications for Clinical Use

(2012) Claire S. Danby et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of pH on the antifungal susceptibility of vaginalCandida albicans

(2011) Wei Liu et al.   INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS

Contemporary perspectives on vaginal pH and lactobacilli

(2010) Iara M. Linhares et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal Infection

(2010) J. L. Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY